1	Secondary pneumonia in critically ill ventilated patients with COVID-19
2	
3	Mailis Maes ^{1*} , Ellen Higginson ^{1*} , Joana Pereira-Dias ^{1*} , Martin Curran ² , Surendra Parmar ² ,
4	Fahad Khokhar ¹ , Delphine Cuchet-Lourenço ³ , Janine Lux ³ , Sapna Sharma-Hajela ⁴ , Benjamin Ravenhill ⁴ ,
5	Razeen Mahroof ⁴ , Amelia Solderholm ¹ , Sally Forrest ¹ , Sushmita Sridhar ^{1,5} , Nicholas Brown ² , Stephen Baker ¹ ,
6	Vilas Navapurkar ⁴ , Gordon Dougan ¹ , Josefin Bartholdson Scott ¹ , Andrew Conway-Morris ^{3,4#}
7	
81	¹ Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine,
9	University of Cambridge, Cambridge, United Kingdom
10	² Public Health England, Clinical Microbiology and Public Health Laboratory, Addenbrookes Hospital,
11	Cambridge, United Kingdom
122	³ Department of Medicine, University of Cambridge, Cambridge, United Kingdom
133	⁴ John Farman ICU, Addenbrookes Hospital, Cambridge, United Kingdom
144	⁵ Wellcome Sanger Insitute, Hinxton, United Kingdom
15	
16	*Contributed equally to the paper
17	# Corresponding author
18	Andrew Conway Morris
19	Division of Anaesthesia
20	Department of Medicine
21	Level 4, Addenbrooke's Hospital
22	Hills Road
23	Cambridge
24	CB2 0QQ
25	Email: ac926@cam.ac.uk
26	Phone: +44 (0)1223 217889
27	
28	

29 Running title: Secondary pneumonia in COVID-19 patients.

30	Word	count:	2630
20		count.	2000

31

32 Author statement

- 33 We studied the microbial composition and diagnostic microbiology results of bronchoalveolar lavage
- 34 (BAL) samples taken from adult COVID-19 patients and COVID-19 negative patients receiving
- 35 artificial ventilation in a teaching hospital ICU. We observed that although COVID-19 patients had a
- 36 greater incidence of VAP, the associated causative pathogens were similar in both groups.

37

- 38 Keywords:
- 39 COVID-19, SARS-CoV-2, coinfections, microarray, VAP, ICU.
- 40
- 41 Abstract

42 Background Pandemic COVID-19 caused by the coronavirus SARS-CoV-2 has a high incidence of

43 patients with severe acute respiratory syndrome (SARS). Many of these patients require admission to

44 an intensive care unit (ICU) for invasive artificial ventilation and are at significant risk of developing

45 a secondary, ventilator-associated pneumonia (VAP).

46 **Objectives** To study the incidence of VAP, as well as differences in secondary infections, and

47 bacterial lung microbiome composition of ventilated COVID-19 and non-COVID-19 patients.

48 Methods In this prospective observational study, we compared the incidence of VAP and secondary

49 infections using a combination of a TaqMan multi-pathogen array and microbial culture. In addition,

50 we determined the lung microbime composition using 16S RNA analysis. The study involved

51 eighteen COVID-19 and seven non-COVID-19 patients receiving invasive ventilation in three ICUs

52 located in a single University teaching hospital between April 13th 2020 and May 7th 2020.

53 **Results** We observed a higher percentage of confirmed VAP in COVID-19 patients. However, there

54 was no statistical difference in the detected organisms or pulmonary microbiome when compared to

55 non-COVID-19 patients.

56 **Conclusion** COVID-19 makes people more susceptible to developing VAP, partly but not entirely

57 due to the increased duration of ventilation. The pulmonary dysbiosis caused by COVID-19, and the

- 58 array of secondary infections observed are similar to that seen in critically ill patients ventilated for
- 59 other reasons.
- 60
- 61 Abstract word count: 209
- 62
- 63

64 Background

65	Pandemic COVID-19 is associated with a high number of patients suffering from severe acute
66	respiratory syndrome (SARS). Such patients can spend significant periods of time in intensive care
67	units (ICU), with >80% of patients admitted to ICU requiring invasive mechanical ventilation [1,2].
68	Critically ill patients are at high risk of nosocomial pneumonia, especially when ventilated [3]. The
69	reasons for this includes breach of natural defences by invasive devices [4], sedation and impairment
70	of coughing and mucociliary clearance, and the immunoparetic effects of critical illness [5,6]. Early
71	reports indicated that critically ill patients infected with SARS-CoV-2 had a high prevalence of
72	nosocomial pneumonia, especially ventilator-associated pneumonia (VAP) [7]. This is likely
73	influenced by the widespread use of corticosteroids and empiric immunosuppressive medication
74	together with increased prevalence of co-morbid conditions [7] and the prolonged duration of
75	artificial ventilation [2].
76	
77	The management of critically ill patients with COVID-19 requires the identification, or exclusion, of
78	bacterial, viral or fungal pathogens which may be present as co-infections on presentation or arise
79	later in the course of the disease. Ventilator-associated pneumonia (VAP) can be challenging to
80	diagnose as a range of non-infectious diseases may mimic the clinical picture of radiographic
81	infiltrates, systemic inflammation and impaired oxygenation that typifies VAP [8]. To limit
82	overdiagnosis and facilitate appropriate antimicrobial therapy in VAP, most centres use culture- based
83	approaches [9,10]. However, molecular tests to detect multiple pathogens (viruses and bacteria) are
84	becoming more accessible and may further reduce unnecessary antimicrobial therapy [11].
85	Additionally, the choice of diagnostic sample is critical and directed bronchoscopy can limit
86	contamination from the proximal airway [12]. An observation that the rate of VAP amongst patients
87	with COVID-19 appeared to be higher than our background rate led to the institution of a minimally-
88	aerosol generating bronchoscopic sampling procedure to seek to minimise over-diagnosis inherent in

89 endo-tracheal aspirate-based sampling [12].

91	In this study, we aimed to identify and compare the distribution of secondary infections and VAP in
92	critically ill ventilated COVID-19 patients against ventilated non-SARS-CoV-2 infected patients. We
93	performed conventional microbiology, multi-pathogen molecular testing, and assessed the
94	composition of the bacterial lung microbiome in bronchoalveolar lavage (BAL) samples of COVID-
95	19 positive and COVID-19 negative patients in the same hospital over a certain time period.
96	
97	Materials and methods
98	
99	Setting and study design
100	This study was a performed in three adult ICUs in Addenbrooke's Hospital, Cambridge, UK,
101	consisting of a liver/general unit, neurotrauma unit and a surge capacity COVID unit. Units had
102	routinely audited ventilator bundles in place, which included sub-glottic suction tubes, mandated
103	twice daily oral hygiene with fluoride toothpaste, daily sedation holds and head of bed elevation.
104	Patients from April 13 th to May 7 th were included in the study if the treating clinician was
105	undertaking BAL for the diagnosis of respiratory infection in a ventilated patient. All patients had X-
106	ray infiltrates and features of systemic inflammation (raised white cell count, temperature >38°C,
107	raised C-reactive protein and/or raised serum pro-calcitonin levels).
108	
109	BALs were conducted in accordance with a modified unit protocol designed to minimise aerosol
110	generation. Briefly, staff members wearing appropriate personal protective equipment (PPE) inserted
111	a pre-loaded bronchoscope through an endotracheal tube catheter mount. The bronchoscope was
112	wedged in a sub-segmental bronchus corresponding to the region of maximal infiltrate on plain
113	radiography. Up to 200ml of saline was instilled and aspirated.
114	
115	Diagnostics
116	Samples for routine microbiology were processed according to the UK Standards for Microbiology
117	Investigations [13]. Any significant growth with a CFU of $>10^4$ /mL was identified by MALDI-ToF
118	mass spectrometry.

117

120 RNA/DNA extraction and SARS-CoV-2 qPCR

121	500µl of BAL was subjected to RNA/DNA extraction following an existing method [14]. Viscous
122	samples were first treated with 10% v/v mucolysin, before 500 μ l lysis buffer (25mM Tris-HCL+ 4M
123	Guanidine thiocyanate with 0.5% b-mercaptoethanol) and glass beads were added to each sample.
124	Tubes were vortexed, and 100% analytical grade ethanol was added to a final concentration of 50%.
125	After a 10 min incubation, 860µl of lysis buffer (containing MS2 as an internal extraction and
126	amplification control) was added. This was then run over an RNA spin column as previously
127	described [14]. SARS-CoV-2 specific real-time RT-PCR was performed and interpreted as
128	previously described [14].
129	
130	TaqMan multi-pathogen array
131	Custom designed TaqMan Array Cards (TAC; Thermo Fisher Scientific) targeting 52 different
132	common respiratory pathogens, were used to test for secondary infections as previously described
133	[15] with modifications. Fifty microlitres of extracted nucleic acid was used in a 200 μ l final reaction
134	volume with TaqMan [™] Fast Virus 1-step Master Mix (Thermo Fisher Scientific), and cards were run
135	on the QuantStudio 7 Flex platform (Thermo Fisher Scientific) as per the manufacturer's instructions.
136	Detection of a clear exponential amplification curve with a Cycles to Threshold (CT) value \leq 32 for
137	any single gene target was reported as a positive result for the relevant pathogen. In those patients
138	who had BALs obtained more than once, new pathogens identified in later samples were added to the
139	results of the initial array.
140	

141 VAP diagnosis

142 The definition of VAP was adapted from the European Centre for Disease Control criteria [16]. VAP

143 was determined to be present in those patients with clinical evidence of pulmonary inflammation,

144 radiographic evidence of lung infiltrates and detection of significant amounts of pathogenic bacterial

145 or fungal species. Clinically significant amounts of pathogen were defined as those detected at a CT

		4	
146	1 200 1/ 1 11	growth on culture of $>10^4$ CFU/ml. Low	1 .1
1/16	$v_{a} u_{b} < 37$ and or microbial	σr_{OW} th on culture of $\geq 10^{\circ}$ (HII/mI I OW)	hing nathogenicity organisms

- 147 (Enterococcus spp., Candida albicans, non-pneumococcal Streptococci and coagulase negative
- 148 Staphylococci) were reported but not considered a component of VAP [17]. Herpesviridae (Herpes
- simplex, cytomegalovirus and Epstein-Barr virus) were reported but were considered to be
- 150 reactivations and not considered a component of VAP [18].
- 151

152 16S Nanopore sequencing

153 Extracted nucleic acids were concentrated using AMPure XP beads (Beckman Coulter) and 16S DNA

154 libraries prepared using the 16S Barcoding Kit SQK-16S024 (Oxford Nanopore Technologies) as per

- 155 the manufacturer's instructions. Final DNA libraries were loaded onto FLO-MIN106D R9.4.1 flow
- 156 cells and sequencing was performed on a GridION Mk1 for ~36 hours with high accuracy basecalling
- 157 enabled. The resulting fastq files were de-multiplexed with guppy_barcoder v3.6.0 using the --
- 158 require_barcodes_both_ends and --trim_barcodes flags. Porechop v0.2.4
- 159 (https://github.com/rrwick/Porechop) was used to trim adapter and barcode sequences and Nanofilt
- 160 v2.6.0 (De Coster, et. al., 2018) was used to filter the reads by length, 1,400 1,600 bps and a quality
- score of 10. Reads were classified against the Silva 132 99% OTUs 16S database using Kraken2 [19].
- 162 Microbial diversity analyses were carried out in R using packages vegan [20] and metacoder [21].

163

164 **Results**

- 165 During the COVID-19 outbreak we have used a combination of TaqMan multi-pathogen array
- 166 and conventional microbial culture to investigate secondary infections associated with patients
- 167 undergoing ventilation. In our ICU, VAP was suspected in 82% of ventilated patients with COVID-19
- and confirmed by culture or TAC in 49% of these patients, giving an incident density of 26 per 1000
- ventilator days for confirmed VAP and 52 per 1000 ventilator days for suspected VAP. We report in
- 170 more detail the diagnoses made from protected lower respiratory samples analysed by these combined

171 culture-based and molecular techniques.

173	34 BAL samples were taken from 25 patients, of which the clinical and demographic data are
174	summarized in Table 1; five patients were sampled on two occasions and two patients sampled on
175	three occasions over the study period. Nineteen of these samples were SARS-CoV-2 positive by RT-
176	PCR, with a mean CT of 28.3. Fifteen samples tested negative for SARS-CoV-2; however, six of
177	these samples came from patients previously diagnosed with COVID-19 by RT-PCR (Table 2).
178	
179	Amongst the 14 patients with a SARS-CoV-2 positive RT-PCR at time of sampling, nine were
180	confirmed to have VAP on the basis of clinical features and detection of a lung pathogen at a CT \leq 32
181	or by microbial culture $>10^4$ CFU/ml. Of these, one patient incurred two episodes of VAP, first with
182	S. aureus and later with S. maltophilia . Of the seven patients without COVID-19, four developed
183	confirmed VAP. Three of the four patients previously diagnosed with COVID-19 but with negative
184	SARS-CoV-2 RT-PCR at the time of sampling also were confirmed as VAP. (The co-infecting
185	organisms are shown in Table 2).

186

187 Notably, there was no significant difference in the concentration (CT) or distribution of organisms 188 between the COVID-19 positive and negative patients. Although not classed as VAP here, a number 189 of organisms (Enterococcus spp., Candida albicans, non-pneumococcal Streptococci) and reactivated 190 viruses (Herpes simplex), normally regarded as being of low pathogenic potential, were detected in 191 patients (Table 2). In some cases, these were detected alongside classical lung pathogens, whereas in 192 other patients they were the sole organisms detected. There was no clear difference in the prevalence 193 of low-pathogenicity organisms between patients positive or negative for SARS-CoV-2. The mean 194 number of organisms detected by TAC in the COVID positive patients was 1.8 organisms/patient 195 (range 0 - 5), whereas the equivalent number in the COVID negative group was 1.1 organisms/patient 196 (range 0 - 3).

197

To investigate changes in the lung microbiota in the COVID-19 positive and negative patients we
 performed 16S rRNA sequencing on a subset of BAL samples. In general, bacteria detected by TAC

200	or conventional microbiology were abundantly identified in samples by 16S sequencing (Figure 1).
201	When comparing COVID-19 positive to COVID-19 negative patients, there was no specific taxon that
202	was more prevalent in either group. Additionally, the microbiomes of COVID-19 positive patients
203	were not significantly different in either the species richness (alpha diversity) or the microbial
204	composition (beta diversity) to those of COVID-19 negative patients.
205	
206	To investigate changes in the microbiota over the course of infection, we next looked at the microbial
207	composition of BAL samples in individual patients over time. Two patients diagnosed with VAP
208	(patients 1 and 24) showed decreasing species richness over time, as the bacterial pathogen implicated
209	in the illness became the predominant microbe present. For patient 6, the microbial composition
210	shifted significantly over time, as Enterococcus took over from Staphylococcus as the most
211	predominant pathogen. The microbiome composition of patient 24, who was both VAP and COVID-
212	19 negative, was largely stable over time. In general, the lung microbiomes of patients who did not
213	have VAP at the time of sampling (sample 1 from patient 14 and both samples from patient 24) were
214	more diverse than samples from patients who had been diagnosed with VAP.

215

216 **Discussion**

217 COVID-19 is a very new disease in the human population and this has led to an increase in the 218 number of patients in need of active sustained ventilation, which in turn introduces an increased risk 219 of VAP. COVID-19 can present in many different severe manifestations and reports of co-infections 220 vary [22,7]. However, often these reports suffer from a lack of clarity around the severity of illness, 221 location of patients (critical care vs non-critical care), timing of sampling relative to onset of disease 222 and, where applicable, the use of mechanical ventilation [22]. Here, we report on the most severely 223 affected COVID-19 patients who required clinical management on an ICU with mechanical 224 ventilation. We found a high incident density of confirmed (26/1000 ventilator days) and suspected 225 (52/1000 ventilator days) VAP in COVID-19 patients. This is greater than the previously reported 226 rates from units with similar admission profiles and use of ventilator bundles, where incident densities 227 were 6-14/1000 ventilator days for confirmed and 12-32/1000 ventilator days for suspected VAP [23].

Although incident density can correct for duration of ventilation to some extent, it is imperfect and long-staying patients may display different features from shorter staying patients [24]. However, even when compared to reports of patients staying for >14 days [23], incident density for COVID-19 patients remains high.

232

233	At the lung microbiome level, we observed no difference in the composition of organisms between
234	COVID-19 positive and COVID-19 patients who developed VAP. Similarly, the causative pathogens
235	identified using molecular and culture methods, were comparable in both the COVID-19 positive and
236	negative patients. Reassuringly, antibiotic susceptibility of the causative pathogens was similar in the
237	two groups (data not shown) and this meant that conventional antimicrobial regimens could be used.
238	We did detect by TAC assay Aspergillus fumigatus in one patients, with supportive clinical and
239	radiographic features, suggesting genuine fungal infection. This is notable as there is increasing
240	recognition of fungal infections amongst patients with viral pneumonitides [25]. Our data support the
241	concept that COVID-19, in common with other critical illness syndromes requiring mechanical
242	ventilation, induces a pulmonary dysbiosis, leading to overgrowth of enteric and respiratory
243	organisms, many of which are of low pathogenic potential[26,27]. These observations likely reflect
244	intercurrent antimicrobial therapy and a degree of immunoparesis which is also observed in other
245	critical illness states. Systemic inflammation, including activation of complement and release of C5a
246	is a hallmark of severe COVID-19 [7, 28], with excessive C5a release being a key driver of innate
247	immune dysfunction in critically ill patients and predictor of subsequent infections [23,5].
248	
249	Studies reporting on VAP in COVID-19 patients are limited and have not reported the
250	microbiological or diagnostic details of the case [7]; however, it has been suggested that bacterial
251	pneumonia may be facilitated by the use of corticosteroids and empiric immunosuppressive
252	medication. In our setting these medications are not commonly used, yet there remains a high
253	prevalence of bacterial VAP in COVID-19 patients. Although VAP in COVID-19 may present
254	problems of quantity, we did not find evidence in this report of a qualitative difference. Indeed, the
255	microbial profiles of ventilated patients with active SARS-CoV-2, those who had cleared SARS-CoV-

256	2 and those who never had the viral infection were similar on both targeted TAC and 16S rRNA
257	sequencing. Our patients demonstrated similar profiles to those reported by other groups investigating
258	the pulmonary microbiome of ventilated patients [26,29]. The factors which lead to pulmonary
259	dysbiosis in critical illness remain incompletely understood, but may include intercurrent antibiotic
260	use, enteric translocation, pulmonary immune dysfunction and altered clearance [30, 27]. We
261	acknowledge the sample size limitations with our observations and suggest larger studies from
262	distinct geographic locations may help fully understand the risk of developing secondary bacterial
263	infections in patients with severe COVID-19.
264	
265	Conclusion
266	COVID-19 makes people more susceptible to developing VAP, partly but not entirely due to the
267	increased duration of ventilation. The change in lung microbiome and causes of secondary infection
268	are similar to those seen in critically ill patients ventilated for other reasons. Careful sampling of the
269	respiratory tract whilst minimising contamination from the proximal tract, in combination with
270	sensitive diagnostic testing to reduce the risk of false negative cultures will aid antimicrobial
271	optimisation in patients with COVID-19.
272	
273	Ethical approval and consent to participate
274	The TaqMan multi-pathogen array has been adopted as a routine clinical service in our institution
275	following a previous evaluation study. The use of discard samples surplus to that required for clinical
276	testing, and anonymised data review were conducted under the consent waiver granted by Leeds West
277	NHS Research Ethics Committee (ref: 20/YH/0152).
070	

278

279 Acknowledgments

280 Our thanks go out to all the ICU clinicians, nurses and physiotherapists who have ensured proper

281 patient care and sample management even in these hard times, as well as to PHE microbiologists for

282 running standard microbiology tests. Furthermore, the authors wish to thank Mark Wills for his help

as Biological Safety Officer to ensure we work in a safe environment. We also thank Estée Török and

284	Ian Goodfellow for access to consumables and the GridION for Nanopore sequencing, and Satpal
285	Ubhi for help with clinical management. Finally, we wish to acknowledge our funders the NIHR
286	BRC. In addition we would like to acknowledge the grant awarded by Addenbrooke's Charitable
287	Trust for the initial study of the clinical utility of the TaqMan microarray.
288	
289	Authors contributions
290	MM- sample processing, data analysis and manuscript writing; EEH- sample processing, data analysis
291	and manuscript writing; JPD-sample processing and manuscript editing; DCL, JL, AS, SF, SS -sample
292	processing; FK- sample processing and data analysis; SSH, BR, RM- VAP surveillance data
293	collection and clinical management MC,SP, NB- diagnostical data analysis; SB manuscript editing;
294	VN conceived study and clinical management: GD- conceived study and manuscript editing; JBS
295	conceived study, sample processing and manuscript editing ; ACM- conceived study, manuscript
296	writing and clinical management.
297	
298	Consent for publication
299	All authors read and approved the final version for publication.
300	
301	Availability of supporting data
302	Raw sequencing data is available on https://www.ncbi.nlm.nih.gov/bioproject/PRJNA642012
303	
304	Funding
305	This study was funded by the National Institute for Health Research [Cambridge Biomedical
306	Research Centre at the Cambridge University Hospitals NHS Foundation Trust]. The views expressed
307	are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health
308	and Social Care. Dr Conway Morris is supported by a Clinical Research Career Development
309	Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z).
310	
311	Competing interest

- 312 The authors have declared that no competing interests exist.

317 References

- Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of COVID-19 in New York City.
 N Engl J Med. April 2020:NEJMc2010419.
- Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591
 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
 JAMA. 2020;323(16):1574-1578.
- 323 3) Vincent J-L, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection Among Patients
 324 in Intensive Care Units in 2017. *JAMA*. 2020;323(15):1478–10.
- 4) Álvarez-Lerma F, Palomar-Martínez M, Sánchez-García M, et al. Prevention of Ventilator Associated Pneumonia. *Critical Care Medicine*. 2018;46(2):181-188.
- Morris AC, Datta D, Shankar-Hari M, et al. Cell-surface signatures of immune dysfunction
 risk-stratify critically ill patients: INFECT study. *Intensive Care Med.* 2018;44(5):627-635.
- 329 6) Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular
 330 dysfunctions to immunotherapy. *Nat Rev Immunol.* 2013;13(12):862-874.
 331 doi:10.1038/nri3552.
- 332 7) Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
 333 with COVID-19-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. March
 334 2020:1-9. doi:10.1016/S0140-6736(20)30566-3.
- 8) Meduri GU, Maul din GL, Wunderink RG, et al. Causes of fever and pulmonary densities in
 patients with clinical manifestations of ventilator-associated pneumonia. 1994;106(1):221235.
- 338 9) Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT
 339 guidelines for the management of hospital-acquired pneumonia and ventilator-associated
 340 pneumonia: *European Respiratory Journal*. 2017;50(3):1700582.
- 341 10) Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired
 342 and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious
 343 Diseases Society of America and the American Thoracic Society. *Clinical Infectious*344 *Diseases*. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353.

345	11) Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Morris AC. Antimicrobial-associated
346	harm in critical care: a narrative review. Intensive Care Med. January 2020:1-11.
347	12) Morris AC, Kefala K, Simpson AJ, et al. Evaluation of the effect of diagnostic methodology
348	on the reported incidence of ventilator-associated pneumonia. Thorax. 2009;64(6):516-522.
349	doi:10.1136/thx.2008.110239.
350	13) SMI B 57: investigation of bronchoalveolar lavage, sputum and associated specimens
351	https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-
352	lavage-sputum-and-associated-specimens
353	14) Sushmita Sridhar, Sally Forrest, Iain Kean, et al. A blueprint for the implementation of a
354	validated approach for the detection of SARS-Cov2 in clinical samples in academic facilities,
355	bioRxiv 2020.04.14.041319; doi:https://doi.org/10.1101/2020.04.14.041319
356	15) SteenselsD, Reynders M Descheemaeker, et al . Clinical evaluation of a multi-parameter
357	customized respiratory TaqMan® array card compared to conventional methods in
358	immunocompromised patients. Journal of Clinical Virology. 2015;72:36-41.
359	16) Plachouras D, Lepape A, Suetens C. ECDC definitions and methods for the surveillance of
360	healthcare-associated infections in intensive care units. Intensive Care Med. October 2018:1-
361	3.
362	17) Chastre J, Fagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med.
363	2002;165(7):867-903.
364	18) Bruynseels P, Jorens PG, Demey HE, et al. Herpes simplex virus in the respiratory tract of
365	critical care patients: a prospective study. The Lancet. 2014;362(9395):1-6.
366	19) Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome Biol.
367	2019;20(1):257. Published 2019 Nov 28. doi:10.1186/s13059-019-1891-0
368	20) Oksanen, J. (2013). Vegan: ecological diversity. R Project.
369	21) Foster, Z. S., Sharpton, T. J., & Grünwald, N. J. (2017). Metacoder: an R package for
370	visualization and manipulation of community taxonomic diversity data. PLoS computational
371	<i>biology</i> , <i>13</i> (2), e1005404.

- Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with
 coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. *Clin Infec Dis.*
- 374 May 2020.
- 375 23) Morris AC, Hay AW, Swann DG, et al. Reducing ventilator-associated pneumonia in
 376 intensive care: Impact of implementing a care bundle. 2011;39(10):2218-2224.
- 377 24) Nelson JE, Cox CE, Hope AA, Carson SS. Chronic critical illness. *Am J Respir Crit Care*378 *Med*. 2010;182(4):446-454.
- Schauwvlieghe A.F.A.D, Rijnders B.J.A, Philips N. et at. Invasive aspergillosis in patients
 admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet
 Respiratory Medicine July 2018 DOI:https://doi.org/10.1016/S2213-2600(18)30274-1.
- 26) Zakharkina T, Martin-Loeches I, Matamoros S, et al. The dynamics of the pulmonary
 microbiome during mechanical ventilation in the intensive care unit and the association with
 occurrence of pneumonia. *Thorax.* 2017;72(9):803-810.
- 27) Roquilly A, Torres A, Villadangos JA, et al. Pathophysiological role of respiratory dysbiosis
 in hospital-acquired pneumonia. *The Lancet Respiratory Medicine*. 2019;7(8):710-720.
 doi:10.1016/S2213-2600(19)30140-7.
- 388 28) Gao T, Hu M, Zhang X, et al. Highly pathogenic coronavirus N protein aggravates lung
- 389 injury by MASP-2-mediated complement over-activation. *medrxivorg*
- doi:10.1101/2020.03.29.20041962.
- 391 29) Dickson RP, Singer BH, Newstead MW, et al. Enrichment of the lung microbiome with gut
 392 bacteria in sepsis and the acute respiratory distress syndrome. *Nat Microbiol*.
 393 2016;1(10):16113.
- 30) Dickson RP, Huffnagle GB. The Lung Microbiome: New Principles for Respiratory
 Bacteriology in Health and Disease. Goldman WE, ed. *PLoS Pathogens*.
 2015;11(7):e1004923-e1004925.
- 397 31) Jacobs F, Denis O et al. Clinical evaluation of a multi-parameter customized respiratory
- 398 TaqMan® array card compared to conventional methods in immunocompromised patients.
- Journal of Clinical Virology. 2015;72:36-41.

- 400 32) Browne E, Hellyer TP, Baudouin SV, et al. A national survey of the diagnosis and
- 401 management of suspected ventilator-associated pneumonia. BMJ Open Resp Res.
- 402 2014;1(1):e000066.
- 403
- 404

405 Figure Legends

406

- 407 Figure 1 Microbial composition of BAL samples from SARS-CoV-2 positive and negative patients.
- 408 Bacterial 16S genes were sequenced and classified to the genus level using Kraken2. The percent of
- 409 reads mapping to each genus is shown for individual samples from each patient (A), and longitudinal
- 410 samples (1, 2 or 3) from individual patients (B, C, D, E). Individuals were classified as either COVID-
- 411 19 negative, COVID-19 positive, or recovering (previously diagnosed with COVID-19 but SARS-
- 412 CoV-2 negative at time of sample).

- 414 Tables
- 415 Table 1. Clinical and demographic features of reported population.

Characteristic	
Median age (range)	57 (31-73)
Female n(%)	9 (36%)
Antibiotics at time of bronchoscopy n(%)	24 (96%)
Median Fi02 prior to bronchoscopy (range)	0.5 (0.25-0.9)
Alive at end of study	17 (68%)
(remain in ICU)	11
Median Duration of ventilation: days (range)	17 (2-42)
Median duration of ICU admission: days	19 (2-44)
(range)	
Immunocompromised* n(%)	6 (24%)

416

417 *Immunocompromised patients were defined as having active haematological malignancy,

418 neutropaenic malignancy, solid organ or bone marrow transplant and receipt of immunosuppressive

419 medication including corticosteroids for >1 week prior to hospital admission.

		SARS-CoV-	COVID-19			
Patient	Sample	2		Organism with CT<32	Cultured Organism	VAP
Patient 1	1	POS	YES	S. aureus	No significant growth	YES
	2	POS	YES	S. maltophilia	No significant growth	YES
Patient 2	1	POS	YES	H. influenzae	No significant growth	YES
Patient 3	1	POS	YES	K. pneumoniae, S. marcescens, E. coli S. epidermidis	No significant growth	YES
Detient 1	1	POS	YES		No significant growth	NO
Patient 4	2	POS	YES	P. aeruginosa	P. aeruginosa	YES
Patient 5	1	POS	YES	HSV, S. epidermidis, C. albicans	C. albicans	NO
	1	POS	YES	S. aureus, S. epidermidis, Streptococcus spp	S. aureus	YES
Patient 6	2	POS	YES	S. aureus, E. faecium, S. marcescens	S. aureus	YES
	3	POS	YES	S. aureus, E. faecium, HSV	S. aureus, S. maltophilia	YES
Patient 7	1	POS	YES	E. faecium, S. epidermidis	Mixed upper resp. tract flora	NO
Patient 8	1	POS	YES	E. faecium, C. albicans	C. albicans	NO
Detient 0	1	POS	YES	HSV, S. marcescens,	S. marcescens	YES
Patient 9	2	POS	YES	E. faecium, S. marcescens	No significant growth	YES
Patient 10	1	POS	YES	K. pneumoniae	No significant growth	YES
Patient 11	1	POS	YES		No significant growth	NO
Patient 12	1	POS	YES	A. fumigatus, S maltophilia	S. maltophilia	YES
Patient 13	1	POS	YES		No significant growth	NO
	1	POS	YES		No significant growth	NO
Patient 14	2	NEG	YES	K. pneumoniae	K. pneumoniae	YES
	3	NEG	YES	K. pneumoniae	K. pneumoniae	YES
Patient 15	1	NEG	NO	C. albicans	C.albicans	NO
Patient 16	1	NEG	NO		E. coli	YES
Patient 17	1	NEG	NO	S. marcescens	Serratia marcescens	YES
Patient 18	1	NEG	YES	Streptococcus spp, E. Proteus , K. pneumoniae	No significant growth	YES
Patient 19	1	NEG	YES	E. faecium, E. coli	E. coli	YES
Patient 20	1	NEG	YES	Enterobacteriaceae	No significant growth	YES
Patient 21	1	NEG	NO	Streptococcus spp, H. influenzae	No significant growth	YES
Patient 22	1	NEG	NO	H. influenzae, Streptococcus spp, S. aureus	No significant growth	YES
Dationt 22	1	NEG	NO		No significant growth	NO
Patient 23	2	NEG	NO		No significant growth	NO
Patient 24	1	NEG	NO	HSV	HSV	NO
	2	NEG	NO	HSV	No significant growth	NO
Patient 25	1	NEG	YES		No significant growth	NO

421 Table 2:

Figure 1

